Related Experiment Video
Updated: Aug 11, 2026
06:26
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Metabolic Dysfunction-Associated Steatotic Liver Disease Reprograms the Hepatic Metastatic Niche
Mustafa Karabicici1, Ekihiro Seki1,2
1Cedars-Sinai Medical Center, Department of Medicine, California, United States, Los Angeles.
Seminars in Liver Disease
|August 4, 2026
Summary
Metabolic dysfunction-associated steatotic liver disease (MASLD) promotes liver metastasis by altering the liver microenvironment. This creates a permissive niche for cancer spread and recurrence, suggesting new therapeutic targets.
Area of Science:
- Hepatology
- Oncology
- Immunology
Background:
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is an emerging risk factor for liver metastasis.
- The steatotic liver microenvironment influences tumor growth and recurrence for various cancers.
Purpose of the Study:
- To elucidate the mechanisms by which MASLD promotes liver metastasis.
- To identify potential therapeutic strategies targeting the MASLD-driven metastatic niche.
Main Methods:
- Review of clinical and experimental studies.
- Analysis of molecular and cellular changes in the steatotic liver microenvironment.
- Investigation of extracellular vesicle-mediated communication.
Main Results:
- MASLD alters hepatic metabolism, stromal organization, vascular architecture, and immune surveillance, favoring metastasis.
- Lipid overload, ECM remodeling, and immune suppression create a pro-metastatic niche.
- Extracellular vesicles contribute to premetastatic niche formation.
Conclusions:
- MASLD significantly reshapes the liver microenvironment, promoting metastatic colonization and recurrence.
- Targeting metabolic and immune pathways within the steatotic liver may offer novel treatments for liver metastasis.
Related Concept Videos
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:24Liver Regeneration
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:24Overview of Lipid Metabolism
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...